Aspire Biopharma Skyrockets 96% on Pipeline Roadmap, Raised Guidance
The biotech company's shares surged after announcing an ambitious plan for its sublingual drug delivery technology and boosting its 2026 financial outlook.
Shares of Aspire Biopharma (NASDAQ: ASBP) nearly doubled in value, closing up 95.7% at $0.42 after the company announced a milestone roadmap for its drug pipeline and raised its fiscal 2026 guidance. The surge reflects investor optimism in Aspire's proprietary sublingual drug delivery technology, which aims to improve the performance of existing blockbuster drugs.
At the heart of the announcement is Aspire's plan for a for its sublingual high-dose aspirin. This follows positive clinical results showing faster absorption compared to traditional tablets. The company intends to use the FDA's 505(b)(2) regulatory pathway, a strategy that could expedite approval by leveraging existing data on aspirin's safety and efficacy.
"Aspire Biopharma's strategic roadmap is centered on reformulating approved drugs for multi-billion-dollar markets," a company spokesperson stated. Beyond aspirin, the company's pipeline includes a needle-free semaglutide for diabetes and weight management, and a sublingual medication for erectile dysfunction, both with key development milestones slated for 2026. The company’s innovative approach focuses on therapeutic areas where faster drug delivery can .
The ambitious pipeline update was accompanied by a significant financial boost. Aspire Biopharma raised its fiscal 2026 adjusted EPS and sales guidance, signaling strong confidence in its commercial prospects. The company recently reported , beating analyst estimates, and sales of $75.711 million that also surpassed expectations.
Aspire has also been active in securing capital to fund its development plans. The company recently completed a $1 million funding tranche and entered into a separate $9.7 million note purchase agreement with investors. This new funding will support the manufacturing of test products for its sublingual ED medication and a Phase 1 clinical study for its sublingual semaglutide, both expected in 2026. With a clear path forward and fresh capital, Aspire Biopharma is poised to make significant strides in the coming years.